Saturday 17 October 2026
Export LBRX’s income statement to Excel — free account
LB Pharmaceuticals Inc
LBRX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 87.4% and free cash flow fell 579.0%, each against the same quarter a year earlier.
36.74
0.05
+0.14%
Follow LBRX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+4 more TTM periods Free account |
0.00% | 0.00% | 0.00% | (72.07%) | |
| (17.41%) | (16.11%) | (19.80%) | (47.38%) | ||
ROIC |
0.00% | (311.67%) | (220.57%) | (1,304.79%) | |
Return on Tangible Assets |
(8.96%) | (8.33%) | (10.26%) | (25.66%) | |
Free Cash Flow per Share |
(3.96) | (4.38) | (1.79) | (2.75) | |
Free Cash Flow |
(23.02) | (35.26) | (50.43) | (82.83) | |
Capital Expenditures |
(0.25) | (0.05) | (0.06) | (0.43) | |
| Other line items | |||||
Cash ROIC |
(3.68%) | (5.91%) | (6.78%) | (12.55%) | |
Accounts Payable Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.82 | 1.40 | 1.29 | 0.96 | |
Depreciation/Fixed assets |
0.31 | 0.37 | 0.40 | 0.26 | |
Capex/Depreciation |
(0.50) | (0.09) | (0.10) | (0.77) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.92) | (4.38) | (1.78) | (2.73) | |
Capex per Share |
(0.04) | (0.01) | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates